PHN-012 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called PHN-012, an antibody-drug conjugate designed for individuals with certain advanced cancers. The trial aims to determine the safety of PHN-012, its effectiveness against tumors, and how the body processes the drug. Potential participants include those with advanced colorectal, lung, or pancreatic cancer who have tried other treatments without success and have a measurable form of the disease. As a Phase 1 trial, participants will be among the first to receive this treatment, aiding researchers in understanding its effects in people.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot have received systemic anti-cancer therapy within a certain period before starting the trial. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that PHN-012 is likely to be safe for humans?
Research on PHN-012, a new cancer treatment, remains in the early stages, so information about its safety is limited. Early trials primarily ensure the treatment's safety for people. The trial includes thorough safety checks to reduce risks and gather important information.
Currently, there are no specific reports on side effects or how well people tolerate PHN-012, as this is its first test in humans. If it had been approved for another condition, it might suggest some level of safety, but that is not the case here.
While specific data is not yet available, the trial's strict safety protocols aim to protect participants and carefully assess any potential risks.12345Why do researchers think this study treatment might be promising?
PHN-012 is unique because it introduces a novel approach to cancer treatment by being administered intravenously, which might allow for more precise delivery and potentially fewer side effects compared to traditional oral medications. Researchers are excited about PHN-012 because it may target cancer cells more effectively, offering a potential improvement over existing therapies like chemotherapy and radiation, which can affect healthy cells as well. This targeted mechanism could lead to better patient outcomes and improved quality of life during treatment.
What evidence suggests that PHN-012 might be an effective treatment for cancer?
Research shows that PHN-012 is a new treatment known as an antibody-drug conjugate (ADC). This treatment combines a protein that targets cancer cells with a drug that can kill them. While limited information from human studies exists, PHN-012 aims to deliver cancer-fighting drugs directly to tumors, potentially protecting healthy cells. Early studies are examining its effectiveness against tumors and its safety. This treatment seeks to offer another option for patients with advanced solid tumors, but further research is needed to confirm its effectiveness.13467
Are You a Good Fit for This Trial?
This trial is for patients with advanced solid tumors like colorectal, non-small cell lung, or pancreatic cancer who've tried at least one systemic therapy and can't use standard treatments anymore or tolerate them. They should have measurable disease, good organ function, be relatively active (ECOG 0-1), and provide a tumor tissue sample.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
PHN-012 is administered intravenously to evaluate safety, tolerability, and anti-tumor activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- PHN-012
Trial Overview
PHN-012, a new antibody-drug conjugate (ADC), is being tested to see how safe it is and if it works against tumors. The study will also look into how the body processes this drug and its effects on the immune system in people with advanced cancers.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
PHN-012 is administered intravenously
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pheon Therapeutics
Lead Sponsor
Citations
A Study of PHN-012 in Patients With Advanced Solid Tumors
The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure.
A Study of PHN-012 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN- ...
PHN-012 for Cancer · Recruiting Participants for Phase ...
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel ...
A Study of PHN-012 in Patients With Advanced Solid
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, ...
5.
ichgcp.net
ichgcp.net/clinical-trials-registry/549145-a-study-of-phn-012-in-patients-with-advanced-solid-tumorsPHN-012 Clinical Trial for Advanced Solid Tumors (Pancreatic ...
The study aims to establish the safety profile, determine appropriate dosage, and assess preliminary efficacy of this novel treatment for patients who have ...
A Study of PHN-012 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN ...
Pheon Therapeutics – Developing next generation ADCs for a ...
Pheon Therapeutics is a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.